[1] DE SOUZA H S P,FIOCCHI C,ILIOPOULOS D.The IBD interactome:an integrated view of aetiology,pathogenesis and therapy[J].Nat Rev Gastroenterol Hepatol,2017,14(12):739-749.
[2] BAUMGART D C,CARDING S R.Inflammatory bowel disease:cause and immunobiology[J].Lancet,2007,369(9573):1627-1640.
[3] DE SOUZA H S,FIOCCHI C.Immunopathogenesis of IBD:current state of the art[J].Nat Rev Gastroenterol Hepatol,2016,13(1):13-27.
[4] LEFEBVRE P,CARIOU B,LIEN F,et al.Role of bile acids and bile acid receptors in metabolic regulation[J].Physiol Rev,2009,89(1):147-191.
[5] GERARD P.Metabolism of cholesterol and bile acids by the gut microbiota[J].Pathogens,2013,3(1):14-24.
[6] RIDLON J M,KANG D J,HYLEMON P B.Bile salt biotransformations by human intestinal bacteria[J].J Lipid Res,2006,47(2):241-259.
[7] DAWSON P A,LAN T,RAO A.Bile acid transporters[J].J Lipid Res,2009,50(12):2340-2357.
[8] CHIANG J Y.Bile acids:regulation of synthesis[J].J Lipid Res,2009,50(10):1955-1966.
[9] TANNOCK G W,TANGERMAN A,VAN SCHAIK A,et al.Deconjugation of bile acids by intestinal lactobacilli[J].Appl Environ Microbiol,1977,33(1):15-18.
[10] SWANN J R,WANT E J,GEIER F M,et al.Systemic gut microbial modulation of bile acid metabolism in host tissue compartments[J].Proc Natl Acad Sci U S A,2011:4523-4530.
[11] SAYIN S I,WAHLSTROM A,FELIN J,et al.Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid,a naturally occurring FXR antagonist[J].Cell Metab,2013,17(2):225-235.
[12] LI F,JIANG C,KRAUSZ K W,et al.Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity[J].Nat Commun,2013,4:2384.
[13] HOFMANN A F,ECKMANN L.How bile acids confer gut mucosal protection against bacteria[J].Proc Natl Acad Sci U S A,2006,103(12):4333-4334.
[14] DUPONT A,HEINBOCKEL L,BRANDENBURG K,et al.Antimicrobial peptides and the enteric mucus layer act in concert to protect the intestinal mucosa[J].Gut microbes,2014,5(6):761-765.
[15] HEGYI P,MALETH J,WALTERS J R,et al.Guts and gall:bile acids in regulation of intestinal epithelial function in health and disease[J].Physiol Rev,2018,98(4):1983-2023.
[16] MERCHANT N B,ROGERS C M,TRIVEDI B,et al.Ligand-dependent activation of the epidermal growth factor receptor by secondary bile acids in polarizing colon cancer cells[J].Surgery,2005,138(3):415-421.
[17] GOLAN M A,LIU W,SHI Y,et al.Transgenic expression of vitamin D receptor in gut epithelial cells ameliorates spontaneous colitis caused by interleukin-10 deficiency[J].Dig Dis Sci,2015,60(7):1941-1947.
[18] ZHOU J,LIU M,ZHAI Y,et al.The antiapoptotic role of pregnane X receptor in human colon cancer cells[J].Mol Endocrinol,2008,22(4):868-880.
[19] SHEN L,WEBER C R,TURNER J R.The tight junction protein complex undergoes rapid and continuous molecular remodeling at steady state[J].J Cell Biol,2008,181(4):683-695.
[20] RAIMONDI F,SANTORO P,BARONE M V,et al.Bile acids modulate tight junction structure and barrier function of Caco-2 monolayers via EGFR activation[J].Am J Physiol Gastrointest Liver Physiol,2008,294(4):G906-913.
[21] MUNCH A,STROM M,SODERHOLM J D.Dihydroxy bile acids increase mucosal permeability and bacterial uptake in human colon biopsies[J].Scand J Gastroenterol,2007,42(10):1167-1174.
[22] MURAKAMI Y,TANABE S,SUZUKI T.High-fat diet-induced intestinal hyperpermeability is associated with increased bile acids in the large intestine of mice[J].J Food Sci,2016,81(1):H216-222.
[23] CIPRIANI S,MENCARELLI A,CHINI M G,et al.The bile acid receptor GPBAR-1(TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis[J].PLoS One,2011,6(10):e25637.
[24] VERBEKE L,FARRE R,VERBINNEN B,et al.The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats[J].Am J Pathol,2015,185(2):409-419.
[25] INAGAKI T,MOSCHETTA A,LEE Y K,et al.Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor[J].Proc Natl Acad Sci U S A,2006,103(10):3920-3925.
[26] JOHANSSON M E,LARSSON J M,HANSSON G C.The two mucus layers of colon are organized by the MUC2 mucin,whereas the outer layer is a legislator of host-microbial interactions[J].Proc Natl Acad Sci U S A,2011:4659-4665.
[27] PELASEYED T,BERGSTROM J H,GUSTAFSSON J K,et al.The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system[J].Immunol Rev,2014,260(1):8-20.
[28] LAUKENS D,DEVISSCHER L,VAN DEN BOSSCHE L,et al.Tauroursodeoxycholic acid inhibits experimental colitis by preventing early intestinal epithelial cell death[J].Lab Invest,2014,94(12):1419-1430.
[29] UBEDA M,LARIO M,MUNOZ L,et al.Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats[J].J Hepatol,2016,64(5):1049-1057.
[30] TERMEN S,TOLLIN M,RODRIGUEZ E,et al.PU.1 and bacterial metabolites regulate the human gene CAMP encoding antimicrobial peptide LL-37 in colon epithelial cells[J].Mol Immunol,2008,45(15):3947-3955.
[31] ENGELHARDT K R,GRIMBACHER B.IL-10 in humans:lessons from the gut,IL-10/IL-10 receptor deficiencies,and IL-10 polymorphisms[J].Curr Top Microbiol Immunol,2014,380:1-18.
[32] WEYLANDT K H,KANG J X,WIEDENMANN B,et al.Lipoxins and resolvins in inflammatory bowel disease[J].Inflamm Bowel Dis,2007,13(6):797-799.
[33] STRAUCH E D,YAMAGUCHI J,BASS B L,et al.Bile salts regulate intestinal epithelial cell migration by nuclear factor-kappa B-induced expression of transforming growth factor-beta[J].J Am Coll Surg,2003,197(6):974-984.
[34] MUHLBAUER M,ALLARD B,BOSSERHOFF A K,et al.Differential effects of deoxycholic acid and taurodeoxycholic acid on NF-kappa B signal transduction and IL-8 gene expression in colonic epithelial cells[J].Am J Physiol Gastrointest Liver Physiol,2004,286(6):G1000-1008.
[35] GELBMANN C M,SCHTEINGART C D,THOMPSON S M,et al.Mast cells and histamine contribute to bile acid-stimulated secretion in the mouse colon[J].J Clin Invest,1995,95(6):2831-2839.
[36] QUIST R G,TON-NU H T,LILLIENAU J,et al.Activation of mast cells by bile acids[J].Gastroenterology,1991,101(2):446-456.
[37] WILDENBERG M E,VAN DEN BRINK G R.FXR activation inhibits inflammation and preserves the intestinal barrier in IBD[J].Gut,2011,60(4):432-433.
[38] ICHIKAWA R,TAKAYAMA T,YONENO K,et al.Bile acids induce monocyte differentiation toward interleukin-12 hypo-producing dendritic cells via a TGR5-dependent pathway[J].Immunology,2012,136(2):153-162.
[39] YONENO K,HISAMATSU T,SHIMAMURA K,et al.TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn's disease[J].Immunology,2013,139(1):19-29.
[40] LE GALL G,NOOR S O,RIDGWAY K,et al.Metabolomics of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome[J].J Proteome Res,2011,10(9):4208-4218.
[41] BJERRUM J T,WANG Y,HAO F,et al.Metabonomics of human fecal extracts characterize ulcerative colitis,Crohn's disease and healthy individuals[J].Metabolomics,2015,11:122-133.
[42] DE PRETER V,MACHIELS K,JOOSSENS M,et al.Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD[J].Gut,2015,64(3):447-458.
[43] KOLHO K L,PESSIA A,JAAKKOLA T,et al.Faecal and serum metabolomics in paediatric inflammatory bowel disease[J].J Crohns Colitis,2017,11(3):321-334.
[44] FRANZOSA E A,SIROTA MADI A,AVILA PACHECO J,et al.Gut microbiome structure and metabolic activity in inflammatory bowel disease[J].Nat Microbiol,2019,4(2):293-305.
[45] DUBOC H,RAJCA S,RAINTEAU D,et al.Connecting dysbiosis,bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases[J].Gut,2013,62(4):531-539.
[46] NOLAN J D,JOHNSTON I M,WALTERS J R.Altered enterohepatic circulation of bile acids in Crohn's disease and their clinical significance:a new perspective[J].Expert Rev Gastroenterol Hepatol,2013,7(1):49-56.
[47] VITEK L.Bile acid malabsorption in inflammatory bowel disease[J].Inflamm Bowel Dis,2015,21(2):476-483.
[48] FRANZOSA E A,SIROTA MADI A,AVILA PACHECO J,et al.Gut microbiome structure and metabolic activity in inflammatory bowel disease[J].Nat Microbiol,2019,4(2):293-305.
[49] 刘姝,王飞.溃疡性结肠炎患者肠道菌群紊乱与Th17/Treg及其分泌炎性细胞因子免疫平衡的关系[J].现代医学,2020,48(7):862-867.
[50] LABBE A,GANOPOLSKY J G,MARTONI C J,et al.Bacterial bile metabolising gene abundance in Crohn's,ulcerative colitis and type 2 diabetes metagenomes[J].PLoS One,2014,9(12):e115175.
[51] FRANK D N,ST AMAND A L,FELDMAN R A,et al.Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases[J].Proc Natl Acad Sci U S A,2007,104(34):13780-13785.
[52] PETERSON D A,FRANK D N,PACE N R,et al.Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases[J].Cell Host Microbe,2008,3(6):417-427.
[53] SOKOL H,LEPAGE P,SEKSIK P,et al.Temperature gradient gel electrophoresis of fecal 16S rRNA reveals active Escherichia coli in the microbiota of patients with ulcerative colitis[J].J Clin Microbiol,2006,44(9):3172-3177.
[54] STENMAN L K,HOLMA R,EGGERT A,et al.A novel mechanism for gut barrier dysfunction by dietary fat:epithelial disruption by hydrophobic bile acids[J].Am J Physiol Gastrointest Liver Physiol,2013,304(3):G227-234.
[55] IGNACIO BARRASA J,OLMO N,PEREZ RAMOS P,et al.Deoxycholic and chenodeoxycholic bile acids induce apoptosis via oxidative stress in human colon adenocarcinoma cells[J].Apoptosis,2011,16(10):1054-1067.
[56] WACHS F P,KRIEG R C,RODRIGUES C M,et al.Bile salt-induced apoptosis in human colon cancer cell lines involves the mitochondrial transmembrane potential but not the CD95(Fas/Apo-1) receptor[J].Int J Colorectal Dis,2005,20(2):103-113.
[57] GRENTEN F R,GRIVENNIKO S I.Inflammation and cancer:triggers,mechanisms,and consequences[J].Immunity,2019,51(1):27-41.
[58] SONG S,BYRD J C,KOO J S,et al.Bile acids induce MUC2 overexpression in human colon carcinoma cells[J].Cancer,2005,103(8):1606-1614.
[59] KLINKSPOOR J H,MOF K S,VAN KLINKEN B J,et al.Mucin secretion by the human colon cell line LS174T is regulated by bile salts[J].Glycobiology,1999,9(1):13-19.
[60] SHEKELS L L,LYFTOGT C T,HO S B.Bile acid-induced alterations of mucin production in differentiated human colon cancer cell lines[J].Int J Biochem Cell Biol,1996,28(2):193-201.
[61] MARTONI C J,LABBE A,GANOPOLSKY J G,et al.Changes in bile acids,FGF-19 and sterol absorption in response to bile salt hydrolase active L.reuteri NCIMB 30242[J].Gut Microbes,2015,6(1):57-65.
[62] JONES M L,MARTONI C J,PARENT M,et al.Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults[J].Br J Nutr,2012,107(10):1505-1513.
[63] GIONCHETTI P,RIZZELLO F,VENTURI A,et al.Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis:a double-blind,placebo-controlled trial[J].Gastroenterology,2000,119(2):305-309.
[64] YASUEDA A,MIZUSHIMA T,NEZU R,et al.The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis[J].Surg Today,2016,46(8):939-949.
[65] BUFFIE C G,BUCCI V,STEIN R R,et al.Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile[J].Nature,2015,517(7533):205-208.
[66] WEINGARDEN A R,DOSA P I,DEWINTER E,et al.Changes in colonic bile acid composition following fecal microbiota transplantation are sufficient to control Clostridium difficile germination and growth[J].PLoS One,2016,11(1):e0147210.
[67] WEINGARDEN A R,CHEN C,BOBR A,et al.Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection[J].Am J Physiol Gastrointest Liver Physiol,2014,306(4):G310-319.
[68] COSTRLLO S P,HUGHES P A,WATERS O,et al.Effect of fecal microbiota transplantation on 8-Week remission in patients with ulcerative colitis:a randomized clinical trial[J].JAMA,2019,321(2):156-164.
[69] PARAMSOTH S,NIELSEN S,KAMM M A,et al.Specific bacteria and metabolites associated with response to fecal microbiota transplantation in patients with ulcerative colitis[J].Gastroenterology,2019,156(5):1440-1454.e2.
[70] PARAMSOTHY S,KAMM M A,KAAKOUSH N O,et al.Multidonor intensive faecal microbiota transplantation for active ulcerative colitis:a randomised placebo-controlled trial[J].Lancet,2017,389(10075):1218-1228.
[71] ROSSEN N G,FUENTES S,VAN DER SPEK M J,et al.Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis[J].Gastroenterology,2015,149(1):110-118.e4.
[72] NUSBAUM D J,SUN F,REN J,et al.Gut microbial and metabolomic profiles after fecal microbiota transplantation in pediatric ulcerative colitis patients[J/OL].FEMS Microbiol Ecol,2018,94(9):fiy133.doi:10.1093/femsec/fiy133.
[73] MI L Z,DEVARAKONDA S,HARP J M,et al.Structural basis for bile acid binding and activation of the nuclear receptor FXR[J].Mol Cell,2003,11(4):1093-1100. |
